Blue Corn Investments
Contributor since: 2012
Company: Individual Investor
Latest Articles
Trillium Therapeutics - A Compelling Investment At Current Levels
Apple Short Interest Has Skyrocketed - Negative Headlines Could Add To It
Geron's Imetelstat: No Threat Now Or Possibly Ever To Incyte's Jakafi Franchise
Incyte: Increasing Sales, Deep Pipeline, Multiple Catalysts, With A Side Of M&A Chatter
Apple Shares Are Ripe For A Pullback - Time To Take Profits
Arena And Vivus Ruined The FDA Approval Run Up For Orexigen
4 Reasons Sangamo Biosciences Is Positioned For A Run-Up
3 Reasons The Apple Launch Disappointed
Qualcomm: Pressures Are Mounting
3D Systems: Down 42% In 2014 And Still A Good Short
3 Reasons Intel Is A More Compelling Investment Than Taiwan Semiconductor
Apple: Shares At All-Time Highs In Bull Market And Still A Great Buy
Best Buy Shares Are Undervalued With Good Growth Prospects
Take-Two Interactive Shares Offer An Incredible Bargain
HP's Q3 Shows PC Recovery Still Going Strong, Confirms Intel Is A Buy
Rackspace Hosting Is A Buy
How Vringo's Reversal At CAFC Just Increased My Confidence In A VirnetX Affirmation
Intel Seeing Some Sweet Tailwinds - Now Is A Great Time To Own Stock
Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential
Signs Point To Affirmation Of VirnetX $368M Jury Award Against Apple At CAFC
Apple Should Secure This Memory Technology Before Its Competition Does
Micron Gets The 'Greenlight' From David Einhorn
Rudolph Technologies: Shares Positioned For 40% Or More Upside For 2014
Epizyme Shares Crater - Present Buying Opportunity
Whale Watch - Seth Klarman's Baupost Group Takes Micron To 32% Of Portfolio
Don't Buy Twitter Now - Wait For The Nosedive
Apple/Microsoft's 'Rockstar Consortium' Attack Google And Android - Who Could Benefit?
Did The Symantec CEO Just Give A 'Tell' Regarding VirnetX?
A Case For Shorting Biopharma Drug Launches: 4 Recent Examples
8 Reasons Why I Expect Molycorp Shares To Double In 1Q 2014
VirnetX Patents Challenged By Recently Formed LLC - A Closer Look
Biolase CEO Takes Dead Aim At Naked Short Sellers - Main Street Cheers